A modular, evidence-grounded framework for rescuing, re-engineering, and accelerating biopharma assets Key Takeaways Blind Spots of Brute Force: Asset redevelopment significantly compresses clinical timelines but capturing this economic premium requires integrating heterogeneous biological, chemical, and clinical evidence into decision-ready evidence packages that conventional empirical screening cannot efficiently produce at scale. TechBio Differentiation: While generic AI

Combining deep learning models with physics-based validation to systematically screen therapeutic protein variants and accelerate developability optimization Key Takeaways Break the “Design-Test-Fail” Loop : Traditional protein optimization is a months-long bottleneck defined by high costs and limited success rates. Apotek Landscape shifts the heavy lifting from the wet lab to our computational platform, identifying low-risk candidates before a single pipette is touched. Iden